Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed. The condition affects 12% of 1.4 million new breast cancer cases annually, leaving its patients with limited treatment options because TNBC doesn't express three protein markers targeted by conventional therapies. The team's findings, published in Clinical Cancer Research, demonstrate that the "HAGE" molecule may have immunogenic qualities beneficial for a TNBC vaccine. Story | More